Biogen’s stock hit by soft guidance and a decline in sales of MS drugs

7 months ago 32
ARTICLE AD BOX
Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset below-consensus EPS outlook.
Read Entire Article
  1. Homepage
  2. Finance
  3. Biogen’s stock hit by soft guidance and a decline in sales of MS drugs

Related

Inflation angst lingers for investors even as Treasury yields are little moved by Fed minutes

Inflation angst lingers for investors even as Treasury yield...

6 hours ago 2
Higher costs, smaller dogs and more cat adoptions are all hitting Freshpet’s sales, analysts say

Higher costs, smaller dogs and more cat adoptions are all hi...

7 hours ago 1
Costco sales run higher after yet another monthly sales gain, helped by digital demand

Costco sales run higher after yet another monthly sales gain...

8 hours ago 1

Trending

1. valentin vacherot
2. san andreas fault
3. fraser bohm
4. mark kelly
5. san diego weather
6. pat spencer
7. kris jenner
8. tanner scott
9. quinten post
10. lj cryer

Popular

Can Pidcock win big & why did it end at Ineos?

Can Pidcock win big & why did it end at Ineos?

7 months ago 326
Netflix scuttles plans to add six previously announced games to its service

Netflix scuttles plans to add six previously announced games...

8 months ago 314
Steam will label early access games that haven't been updated in a year

Steam will label early access games that haven't been update...

8 months ago 274
OpenAI co-founder John Schulman has left Anthropic after less than a year

OpenAI co-founder John Schulman has left Anthropic after les...

8 months ago 273
‘I didn’t want to spend time with my children. I was just going through the motions’: the pain of parental burnout

‘I didn’t want to spend time with my children. I was just go...

7 months ago 268
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Nexa News 2025. All rights are reserved